Analytical Power Tools Open Upstream Bioprocessing Bottlenecks 

The blockbuster success of antibody-based therapeutics for autoimmune diseases, inflammatory diseases and immuno-oncology accelerated the high stakes monoclonal antibody (mAb) development race. Clone selection is a significant upstream bottle-neck slowing bench-to-bedside development progress for new mAb-based therapeutics.

The iQue^® Human IgG Titer & Viability Kit accelerates human mAb production cell-line generation, significantly reducing the time to industrial-scale productivity. The iQue^® Human IgG Titer & Viability Kit assay combined with the iQue^® Advanced Flow Cytometry Platform with iQue Forecyt^® Software are the analytical power tools that inform rapid go | no-go decisions with multiparameter, high-content data from a single-path workflow.